ReSEARCH STUDY

Do you have a patient with myelofibrosis?

Learn about our research studies of an investigational medication targeting myelofibrosis.

transforming lives Myelofibrosis Research
transforming lives Myelofibrosis Research

Our Studies

Patients who are diagnosed with myelofibrosis will experience constitutional symptoms, splenomegaly, and patients with higher risk disease are at an increased risk of transformation to acute myeloid leukemia (AML), and a shortened life expectancy. As an acquired clonal Philadelphia chromosome negative myeloproliferative neoplasm, myelofibrosis can present in a number of ways. Patients may be diagnosed with primary myelofibrosis or secondary myelofibrosis following progression of polycythemia vera (PV) to post-PV myelofibrosis, or essential thrombocythemia (ET) to post-ET myelofibrosis. Other than hematopoietic stem cell transplantation (HSCT), that is a potentially curative therapy, currently available therapies are unable to control all of the clinical manifestations of myelofibrosis. Our research is focusing on potential new treatment options, including combination strategies with ruxolitinib as the backbone treatment.

We are conducting three research studies to evaluate an investigational agent called navitoclax in patients with myelofibrosis. The primary objective of this program is to evaluate the effect of navitoclax (in most cases, in combination with ruxolitinib) on reducing spleen volume in patients with myelofibrosis. Patients may continue on the study treatment as long as they are receiving benefit. We need help from the local medical community to help us identify qualified study participants around the world.

Navitoclax is under clinical development and is not approved by regulatory health authorities. Safety and efficacy have not been established.

Locations

The Myelofibrosis research studies are being conducted at research centers across the globe.

      Connect

      If you would like to learn more about the AbbVie myelofibrosis studies and speak to a Principal Investigator to find out if your patients may be eligible, please complete the form below and you will be contacted by a member of the research team. Thank you for your interest.
      Refine Study for Myelofibrosis

      In the open label single arm Phase 2 REFINE study, the investigational agent (navitoclax) will be administered either alone or in combination with ruxolitinib to evaluate its effect on controlling the signs and symptoms of myelofibrosis including impact on spleen size, blood counts, bone marrow fibrosis and quality of life.

      Eligibility Criteria

      • 18 years of age or older
      • Have been diagnosed with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis
      • Currently have Intermediate-2 or High-Risk myelofibrosis
      • Are ineligible or unwilling to undergo stem cell transplantation
      • Have received prior treatment with ruxolitinib or another JAK-2 inhibitor for myelofibrosis, however, prior treatment is not required for all patients
      • Have splenomegaly of at least 5 cm

      Navitoclax, an investigational agent, is under clinical development and is not approved by regulatory health authorities. Safety and efficacy have not been established.

      AbbVie Myelofibrosis Research Studies

      In the double-blind placebo-controlled Phase 3 TRANSFORM-1 study, the investigational agent (navitoclax) in combination with ruxolitinib will be compared to ruxolitinib with matching placebo, to evaluate its effect on splenomegaly, bone marrow fibrosis, anemia responses and quality of life.

      Eligibility Criteria

      • 18 years of age or older
      • Have been diagnosed with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis
      • Currently have Intermediate-2 or High-Risk myelofibrosis
      • Have not received prior treatment with a JAK-2 inhibitor therapy
      • Have splenomegaly of at least 5 cm

      Navitoclax, an investigational agent, is under clinical development and is not approved by regulatory health authorities. Safety and efficacy have not been established.

      Myelofibrosis Research Study by AbbVie

      In the randomized open-label Phase 3 TRANSFORM-2 study, the investigational agent (navitoclax) in combination with ruxolitinib is compared to best available therapy to evaluate its effect on splenomegaly, bone marrow fibrosis, anemia responses and quality of life in relapsed/refractory myelofibrosis patients.

      Eligibility Criteria

      • Are 18 years of age or older
      • Have been diagnosed with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis
      • Currently have Intermediate-2 or High-Risk myelofibrosis
      • Have received prior treatment with a JAK-2 inhibitor therapy
      • Have splenomegaly of at least 5 cm

      Navitoclax, an investigational agent, is under clinical development and is not approved by regulatory health authorities. Safety and efficacy have not been established.